When it was announced that Nintendo was going to be released a fighting game with motion controls called Arms, many were concerned that the response wouldn’t be up to par. Based on early impressions, however, both the game and the controls seem to be performing well. This should come as a relief to fans of the Switch who might have been worried that its rise to fame might be derailed.
It’s no secret that the Nintendo Switch is on Cloud 9 right now, with the console breaking records at every turn and enthusiasm for ownership still sky high. However, even the smallest details can turn players off from a product and wonky motion controls could be a deal breaker for many. Fortunately, Kotaku and publications like it have judged that such concerns might be unwarranted.
Now, it’s worth noting that this is one game and the controls are about as straightforward as they can be. Even so, critics are still impressed by how well the characters respond to movements in order to perform three basic attacks in Arms.
For those who don’t know, Arms is basically a fighting game where players control characters who use extendable extremities to fight. Players can use both the normal controller scheme or the Joy-Con motion control and it was the latter that the reviewers focused on.
Suffice it to say, most of those who were lucky enough to test the game and the controls were surprised at how good it was. Granted, much of the excellence in the controls had a lot to do with how smart the developers were at taking advantage of the gyro-sensors, IGN notes. Whether it is punching, blocking or throwing, everything worked smoothly.
Of course, getting the hang of the controls does involve a learning curve, so players shouldn’t assume that the game will work perfectly for them without some practice. All in all, the Switch and Arms seem to perform admirably in an area where so much could have gone wrong. Players will know soon enough when the game comes out on June 16th.


SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 



